����������

The Food and Drug Administration on May 3  the first U.S. vaccine for respiratory syncytial virus, Arexvy by GlaxoSmithKline Biologicals, for use in individuals aged 60 and older.  

“Older adults, in particular those with underlying health conditions, such as heart or lung disease or weakened immune systems, are at high risk for severe disease caused by RSV,” said Peter Marks, M.D., director of the FDA’s Center for Biologics Evaluation and Research. “Today’s approval of the first RSV vaccine is an important public health achievement to prevent a disease which can be life-threatening and reflects the FDA’s continued commitment to facilitating the development of safe and effective vaccines for use in the United States.”